CSL – Morgans rates the stock as Add

By Broker News | More Articles by Broker News

CSL’s FY17 full-year results beat the broker thanks to a margin lift on high-value products, strong plasma sales, more efficient operations and a stumble by competitors.

Morgans says expected second-half weakness should give way to a reinvestment year in 2018, and believes forecasts may be conservative.

CSL is upgraded to Add from Hold and the target price eases marginally from $140.20 to $138.40.

Sector: Pharmaceuticals & Biotechnology.

Target price is $138.40.Current Price is $125.27. Difference: $13.13 – (brackets indicate current price is over target). If CSL meets the Morgans target it will return approximately 9% (excluding dividends, fees and charges – negative figures indicate an expected loss).

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →